Equity Overview
Price & Market Data
Price: $4.29
Daily Change: $0.00 / 0.00%
Daily Range: $3.77 - $4.72
Market Cap: $8,243,522
Daily Volume: 31,101
Performance Metrics
1 Week: -4.67%
1 Month: -3.81%
3 Months: -21.54%
6 Months: -24.20%
1 Year: -46.51%
YTD: -21.54%
Company Details
Employees: 23
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline product include BDC-4182, an next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; and BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors including, colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.